Nephro Care India Posts Rs 2.19 Crore PAT In H1FY25

Nephro Care India  (NCIL), a multi-specialty healthcare provider backed by Deepak Parekh, has reported a standalone net profit of Rs 2.19 crore for the first half of the financial year ending September 30, 2024. 

In a press statement on Tuesday, the company said that with its recent listing on the NSE Emerge SME platform in July, half-yearly figures for H1FY24 were not available for comparison. However, NCIL achieved an 85.94 per cent increase in net profit to Rs 4.41 crore for FY24, compared to Rs 2.37 crore in FY23.

The company's revenue from operations for the first half stood at Rs 17.69 crore. For FY24, NCIL’s revenue grew 59.31 per cent, reaching Rs 27.23 crore, up from Rs 17.09 crore the previous year. Its operating profit, EBITDA, was Rs 3.51 crore with an EBITDA margin of 19.35 per cent in H1FY25. NCIL expects further profitability growth as its newly inaugurated multispecialty hospital, Vivacity, moves toward operational profit.

Dr. Pratim Sengupta, MD & CEO of Nephro Care India, highlighted that despite recent investments, including Rs 36.51 crore for the new Vivacity Multispecialty Hospital, the company achieved a strong net profit. “Our revenues from the existing renal care units have seen significant growth. The recent openings of new renal clinics, which typically take around six months to break even, and the inauguration of our multispecialty hospital, Vivacity, are positive steps. We anticipate increased profitability in the coming quarters as these units reach operational profit,” Dr. Sengupta stated.

Currently operating four renal care units in West Bengal, NCIL plans to open two more clinics in Shyambazar, Kolkata, and Balasore, Odisha, by the fiscal year-end. “We are progressing rapidly at both sites and hope to commence operations soon,” said Dr. Sengupta.

The company's statement further highlighted that in India, the prevalence of high blood sugar and hypertension poses a major risk for renal disease, with government data indicating that 2,20,000 patients develop end-stage renal disease (ESRD) annually, creating demand for 34 million dialysis sessions. Existing infrastructure includes around 5,000 dialysis centres, including 1,353 under the PM National Dialysis Program (PMNDP), which remains insufficient to meet this rising demand, Dr. Sengupta added, emphasising the need for more comprehensive renal care centres.